Severe eosinophilia associated with hydroxychloroquine use in a patient with COVID-19

• 作者: Resat Ozaras Altan Bayar Niiar Alioglu Semiha Baysoy
• 来源期刊: 亚太热带医药杂志（英文版）
• 年，卷（期）: 2021,（6）
• 所属期刊栏目: Letter to Editor
• 页码范围: 285-286
• 页数: 2页
• 语种: 英文
• DOI: 10.4103/1995-7645.314112

摘要

Hydroxychloroquine, a 4-aminoquinoline derivative, is indicated in systemic lupus erythematosus, rheumatoid arthritis and other inflammatory rheumatic diseases[1]. Its main adverse drug reactions are retinopathy during long-term exposure with high doses, cardiac damage with arrhythmias, potentially severe skin damage, neuromyopathy, and hematological damage such as bone marrow aplasia and agranulocytosis[2]. Eosinophilia, although very rare, is a known side effect of this drug[3]. We came across a case of severe eosinophilia without skin manifestations during the treatment of COVID-19 with hydroxychloroquine.